ANS-858
Alcohol Use Disorder (AUD)
PreclinicalActive
Key Facts
About Amygdala Neurosciences
Amygdala Neurosciences is pioneering a novel pharmacological approach to treating addiction by targeting the aldehyde dehydrogenase type 2 (ALDH2) enzyme. Its lead asset, ANS-858, is an oral, reversible ALDH2 inhibitor in preclinical development with potential applications across multiple substance use disorders, starting with alcohol use disorder. The company is led by a seasoned management team with deep experience in founding, developing, and commercializing successful biotech ventures. Amygdala's strategy is based on the premise that ALDH2 inhibition can reduce cravings and relapse, addressing a significant unmet medical need in a large and underserved market.
View full company profileTherapeutic Areas
Other Alcohol Use Disorder (AUD) Drugs
| Drug | Company | Phase |
|---|---|---|
| KT-110 | Kinnov Therapeutics | Phase 2 |
| KT-110 (New Galenic Form) | Kinnov Therapeutics | Formulation Testing |
| TMP-301 | Tempero Bio | Phase 1 |
| iSTEP-N | Akyso Therapeutics | Pre-clinical |
| Varenicline/Bupropion Combination | Sobrera Pharma | Phase 2 |
| TNX-102 SL | Tonix Pharmaceuticals | Phase 2 |
| SVN-015 | Solvonis Therapeutics | Pre-clinical |